Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG), highlighting the company's progress with ZUNVEYL in the long-term care market. The update follows Alpha Cognition's fiscal year 2025 results, which demonstrated increasingly durable traction for ZUNVEYL, an oral therapy for Alzheimer's disease.
In the fourth quarter of 2025, net product revenue from ZUNVEYL reached $2.5 million, contributing to a total FY25 revenue of $10.2 million, which included $6.8 million in ZUNVEYL sales. More notably, demand indicators continued to inflect positively. Bottles dispensed rose 62% quarter-over-quarter to 4,941, with December alone reaching a record 1,859 bottles. This growth underscores the increasing adoption of ZUNVEYL in long-term care facilities.
Repeat ordering remained strong, supporting management's view that ZUNVEYL is moving beyond early trial use and becoming more embedded in facility treatment protocols. According to the announcement, there were 729 ordering homes, 82% repeat orders, and 865 prescribers with 69% repeat writers. These metrics suggest that ZUNVEYL is gaining acceptance among healthcare providers and facilities, which is critical for sustained revenue growth.
Alpha Cognition is well-funded to continue scaling its commercialization efforts. The company ended FY25 with $66.0 million in cash, providing runway into 2027. Management expects continued sequential sales growth in 2026, indicating confidence in the drug's market penetration and the company's commercial strategy.
The full announcement, including downloadable images and bios, is available here. Stonegate Capital Partners, through its affiliate Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.
